ABMC Phone: 800-227-1243

518-758-8158

Drug Tests 100% Manufactured in the USA

ABMC Reports Fourth Quarter and Fiscal Year End 2010 Results

KINDERHOOK, N.Y. - March 24, 2011 - American Bio Medica Corporation (Pink Sheets: ABMC) today announced financial results for the fourth quarter and the year ended December 31, 2010.

Net sales for the fourth quarter of 2010 were $2,340,000, an increase of $177,000, or 8.2%, from net sales of $2,163,000 reported in the fourth quarter of 2009. Operating loss for the fourth quarter of 2010 was $290,000 compared to an operating loss of $114,000 reported in the fourth quarter of 2009. Net loss for the fourth quarter of 2010 was $342,000, or $0.02 per share, compared to a net loss of $189,000, or $0.01 per share, for the fourth quarter of 2009.

Net sales for the year ended December 31, 2010 were $10,421,000 compared to $9,726,000 for the year ended December 31, 2009, representing an increase of $695,000, or 7.2%. Operating loss for 2010 was $534,000, compared to an operating loss of $672,000 in 2009. Net loss for the year ended December 31, 2010 was $750,000, or $0.03 per share, compared to a net loss of $900,000, or $0.04 per share, for the year ended December 31, 2009.

ABMC Chief Executive Officer, Stan Cipkowski, stated, "While we are pleased with the improvement in sales and operating results in 2010, sales for 2010 were still down from pre-recession levels. Given the continued uncertainty of the economy, we remain unsure as to when we will see sustained sales improvement. In addition to facing general market conditions, we must deal with the government’s attempts to regulate workplace drug testing, one of our core markets. We are hopeful that we will work through market regulatory issues and find new opportunities to generate sales while continuing to focus efforts on controlling costs."

Conference Call

The Company will host a conference call and webcast to discuss year-end and fourth quarter 2010 results on Friday, March 25, 2011 at 11:00 am (ET). Investors and interested parties are invited to participate. The call will be broadcast live over the internet at www.abmc.com/investor/. The webcast will be listen-only mode. Listeners are requested to be online at least fifteen minutes early to register, as well as to download and install any complimentary audio software that might be required. To ask questions, you are invited to participate by phone. Within North America, dial 866-792-1873 and internationally dial 904-520-5760. The call will be available for replay at www.abmc.com/investor/ for 30 days.

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® and Rapid STAT™ tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to "penny stock" rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-K for the fiscal year ended December 31, 2009, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

(financial tables follow)

American Bio Medica Corporation
Statements of Operation
(in thousands, except earnings per share)
Three Months Ended Year Ended
December 31, December 31,
2010 2009 2010 2009
(unaudited) (unaudited) (unaudited)
Net sales $ 2,340 $ 2,163 $ 10,421 $ 9,726
Cost of goods sold 1,521 1,148 6,313 5,611
Gross profit 819 1,015 4,108 4,115
Operating expenses:
Research and development 53 102 297 418
Selling and marketing 497 466 2,030 2,052
General and administrative 559 561 2,315 2,317
Total operating expenses 1,109 1,129 4,642 4,787
Operating loss (290) (114) (534) (672)
Other income/(expense) - net (52) (74) (212) (227)
Net loss before tax (342) (188) (746) (899)
Income tax expense (1) (4) (1)
Net loss $ (342) $ (189) $ (750) $ (900)
Basic & diluted loss per common share $ (0.02) $ (0.01) $ (0.03) $ (0.04)
Basic & diluted weighted average shares outstanding 21,745 21,745 21,745 21,745

(Balance Sheets follow)

American Bio Medica Corporation
Balance Sheets
(in thousands)
December 31, December 31,
2010
(unaudited)
2009
ASSETS
Current Assets
Cash and cash equivalents $ 37 $ 35
Accounts receivable, net of allowance for doubtful accounts
of $76,000 at December 31, 2010 and $67,000 at December 31,
2009

743

816

Inventory, net of allowance for slow moving and obsolete
inventory of $213,000 at December 31, 2010 and $271,000 at
December 31, 2009

3,604

4,315

Prepaid expenses and other current assets 121 101
Total current assets 4,505 5,267
Property, plant and equipment, net 1,409 1,624
Debt issuance costs, net 72 118
Other assets 29 31
Total assets $ 6,015 $ 7,040
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable 432 $ 678
Accrued expenses and other current liabilities 287 506
Wages payable 252 215
Line of credit 493 260
Current portion of long-term debt and unearned grant 140 117
Total current liabilities 1,604 1,776
Other liabilities 140 136
Long-term debt 1,480 1,606
Related party note 124 124
Unearned grant 10 20
Total liabilities 3,358 3,662
Stockholders' Equity:
Common stock 217 217
Additional paid-in capital 19,328 19,299
Accumulated deficit (16,888) (16,138)
Total stockholders’ equity 2,657 3,378
Total liabilities and stockholders' equity $ 6,015 $ 7,040

Contact:
American Bio Medica Corporation
Stan Cipkowski, 800-227-1243, Ext 106
Chief Executive Officer